These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25726571)

  • 1. Factors determining non-compliance to mass drug administration for lymphatic filariasis elimination in endemic districts of Nepal.
    Adhikari RK; Sherchand JB; Mishra SR; Ranabhat K; Devkota P; Mishra D; Ghimire YC; Gelal K; Mishra R; Paudel R; Wagle RR
    J Nepal Health Res Counc; 2014; 12(27):124-9. PubMed ID: 25726571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Awareness and coverage of mass drug administration for elimination of lymphatic filariasis: a community based cross sectional study in Nepal.
    Adhikari RK; Sherchand JB; Mishra SR; Ranabhat K; Wagle RR
    J Community Health; 2015 Feb; 40(1):34-40. PubMed ID: 24996654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of microfilaremia in 'hotspots' of four lymphatic filariasis endemic districts of Nepal during post-MDA surveillance.
    Mehta PK; Maharjan M
    PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011932. PubMed ID: 38295107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
    Dicko I; Coulibaly YI; Sangaré M; Sarfo B; Nortey PA
    Infect Disord Drug Targets; 2020; 20(2):167-174. PubMed ID: 30727921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
    Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
    Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
    Nandha B; Krishnamoorthy K; Jambulingam P
    Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study.
    Lahariya C; Mishra A
    J Vector Borne Dis; 2008 Dec; 45(4):313-20. PubMed ID: 19248659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs.
    Cantey PT; Rout J; Rao G; Williamson J; Fox LM
    PLoS Negl Trop Dis; 2010 Jun; 4(6):e728. PubMed ID: 20628595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
    Ojha CR; Joshi B; Kc KP; Dumre SP; Yogi KK; Bhatta B; Adhikari T; Crowley K; Marasini BR
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005788. PubMed ID: 28723904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphatic filariasis elimination programme in Andaman and Nicobar Islands, India: drug coverage and compliance post eight rounds of MDA.
    Sunish IP; Shriram AN; Sivan A; Kartick C; Saha BP; Vijayachari P
    Trop Doct; 2013 Jan; 43(1):30-2. PubMed ID: 23550201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.
    Biritwum NK; de Souza DK; Marfo B; Odoom S; Alomatu B; Asiedu O; Yeboah A; Hervie TE; Mensah EO; Yikpotey P; Koroma JB; Molyneux D; Bockarie MJ; Gyapong JO
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005280. PubMed ID: 28333930
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
    Dorkenoo AM; Sodahlon YK; Bronzan RN; Yakpa K; Sossou E; Ouro-Medeli A; Teko M; Seim A; Mathieu E
    Bull Soc Pathol Exot; 2015 Aug; 108(3):181-7. PubMed ID: 25476256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge and practice related to compliance with mass drug administration during the Egyptian national filariasis elimination program.
    Abd Elaziz KM; El-Setouhy M; Bradley MH; Ramzy RM; Weil GJ
    Am J Trop Med Hyg; 2013 Aug; 89(2):260-4. PubMed ID: 23751402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving community participation to eliminate lymphatic filariasis in American Samoa.
    King JD; Zielinski-Gutierrez E; Pa'au M; Lammie P
    Acta Trop; 2011 Sep; 120 Suppl 1():S48-54. PubMed ID: 20932818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coverage and compliance of mass drug administration (MDA) programme for elimination of lymphatic filariasis in an endemic district of eastern Uttar Pradesh, India.
    Bashar A; Nandekar SV; Shrivastava P; Singh RN; Srikrishnan P
    J Vector Borne Dis; 2023; 60(3):307-316. PubMed ID: 37843242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of community empowerment in the elimination of lymphatic filariasis in south India.
    Rajendran R; Sunish IP; Munirathinam A; Ashok Kumar V; Tyagi BK
    Trop Biomed; 2010 Apr; 27(1):68-78. PubMed ID: 20562816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.
    Njomo DW; Kimani BW; Kibe LW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009012. PubMed ID: 33370300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.
    Ramaiah KD; Vijay Kumar KN; Hosein E; Krishnamoorthy P; Augustin DJ; Snehalatha KS; Nanda B; Das PK
    Ann Trop Med Parasitol; 2006 Jun; 100(4):345-61. PubMed ID: 16762115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
    Rebollo MP; Bockarie MJ
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):723-31. PubMed ID: 23879610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.